ObsEva (NASDAQ:OBSV) and Silverback Therapeutics (NASDAQ:SBTX) Head-To-Head Survey

Earnings & Valuation

This table compares ObsEva and Silverback Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38 million	($0.92)	N/A
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-3.37

Silverback Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ObsEva and Silverback Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Institutional & Insider Ownership

17.5% of ObsEva shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.